NEW YORK (GenomeWeb) – Next-generation sequencing-based diagnostics firm Guardant Health today announced it raised $30 million in a Series B financing.

Khosla Ventures led the round and was joined by existing investor Sequoia Capital and new investor Pejman Mar Ventures.

The financing "will allow Guardant Health to accelerate the expansion of its commercial operations to support growing demand and ensure a distinctively high level of service for our physicians and patients," Guardant CEO and Co-Founder Helmy Eltoukhy said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.